Sentence examples for conducted proof of from inspiring English sources

To assess the ability of anti-adhesive agents to modify drug penetration, we conducted proof of principle experiments in MCC, using the calcium chelating agent EGTA, which disrupts E-cadherin mediated cell adhesion.

Hence, we conducted proof of concept laboratory studies using DADS in a chondrosarcoma cell line, measuring both cellular acetylation and its ability to repress the IL-1/OSM-induced expression of key matrix-degrading metalloproteinases as a surrogate for the destruction/protection of articular cartilage.

This facility has already conducted proof-of-principle quantum communication experiments utilizing laser signals bounced off retroreflectors mounted on existing satellites [60].

In summary, we have conducted proof-of-concept analyses to determine whether genetic information can be used to bring us one step closer towards personalized HIV medicine.

In this report we conducted proof-of-principle studies by cross-breeding transgenic mouse strains known to be predisposed to the development of mammary gland tumors, the MMTV-neu [18] and Beclin1 +/− [19] mouse strains, with the ODD-luciferase mice developed by Safran, et al. and subsequently characterized tumors via bioluminescent monitoring.

> > -wrap-foot> We conducted proof-of-principle tests with 1000 Genomes-imputed 38.02 million markers [ 11], 873 individuals and 44 clinical traits of blood and all of their ratios to validate RegScan.

Using the B16F10 melanoma preclinical model, we conducted proof-of-concept experiments to demonstrate a process for somatic mutation identification, mutation selection, and on-demand individualised vaccine production (Castle et al, 2012).

Collecting large datasets and validating the use of them in carefully conducted proof-of-principle studies using efficacious vaccines with a known correlate of protection is the key for validating the use of high-throughput methods for the assessment of future vaccines.

Here, we used well-defined human CD33+ AML cell lines and genetically engineered sublines to test the impact of inhibitory (PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273)) and activating (CD80 (B7-1) and CD86 (B7-2)) T-cell ligands on the cytolytic activity of AMG 330 in vitro, and then conducted proof-of-principle studies in specimens obtained from patients with AML.

Many investigators rely on intra-mural funding and donated academic effort to conduct proof-of-concept pilot studies.

Tox21 investigators are now conducting proof-of-principle experiments to show that pathway perturbations can predict toxicities already documented in completed animal studies.